Close Menu

MDRNA

Among the firms exploring areas outside of their core RNAi drug focus are Alnylam Pharmaceuticals, Marina Biotech, and RXi Pharmaceuticals.

MDRNA, now known as Marina Biotech, plans a 1-for-4 reverse stock split, which will enable it to have enough authorized shares to consummate the acquisition of Cequent.

Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.

Rosetta Genomics said that its chief commercialization officer would resign as the company settles into its latest change in corporate direction. But the company is not the only player in the RNAi/microRNA space to experience changes to its management lineup.

"We've established the intellectual property portfolio and basis to be an integrated personalized medicine company focused in nucleic acid therapeutics and diagnostics," President and CEO Michael French told Gene Silencing News.

Today's announcement and previously obtained exclusive rights to CRN technology for both therapeutics and diagnostics gives MDRNA one of the few intellectual property portfolios that support a nucleic acid-based personalized medicine platform and the ability to pursue proprietary nucleic acid-based therapeutics and diagnostics, the company said.

The drop in revenues reflects the receipt of milestones and licensing fees from partners Novartis, Roche, and Amylin Pharmaceuticals in the year-ago quarter, which were not received this year.

The arrangement will focus on the use of MDRNA's DiLA2 delivery technology with proprietary miRNAs in "experimental oncology models."

According to MDRNA, the application claims siRNAs and delivery systems with therapeutic potential.

"We believe [the FAP drug] is a product that the combined company could commercialize with a small specialty sales force [with] minimal sales and marketing infrastructure," MDRNA's President and CEO Michael French said this week.

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.